Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence. Objective SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population. Design/setting The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide. Intervention Once-weekly semaglutide was prescribed at the physicians’ discretion. Main outcomes The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). Secondary endpoints included changes in body weight and patient-reported outcomes. All adverse events were systematically collected and reported, including patient-reported documented and/or severe hypoglycaemia. Results Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set. In this data set, estimated mean changes in glycated haemoglobin and body weight from baseline to end-of-study were –1.0%point (–10.9 mmol/mol; P<0.0001) and –4.5 kg (–4.2%; P<0.0001). Sensitivity analyses supported the primary analysis. Improvements were observed in other secondary endpoints, including patient-reported outcomes. No new safety concerns were identified. Conclusions In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support the use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The goals of T2D treatment are to prevent or delay complications and to maintain quality of life via glycaemic control and cardiovascular (CV) risk factor management [2].”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 714
Cited by
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Case Report: Semaglutide-associated depression: A report of two cases
Li, J.-R., Cao, J., Wei, J., & Geng, W. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1238353 · Cited by 50
“There have been also some reports of rare adverse events including hyperglycemia, acute pancreatitis, and acute nephritis (5, 8, 9).”
BackgroundPantanetti, P., Cangelosi, G., Alberti, S., Marco, S. D., Michetti, G., Cerasoli, G., Giacinti, M. D., Coacci, S., Francucci, N., Petrelli, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394506 · Cited by 51
Mohammedi, K., Belhatem, N., Berentzen, T. L., Catarig, A., & Potier, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15045 · Cited by 25
Self-citationWang, S., Wang, S., Wang, Y., & Luan, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01520-3 · Cited by 27
Yale, J., Major‐Pedersen, A., Catarig, A., Jain, R., Menzen, M., & Holmes, P. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15794 · Cited by 20
Self-citationKurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
Butt, M. I., Alkhalifah, K., Riazuddin, M., Almuammar, S. M., Almuammar, S. M., Alhifthi, G. A., Ahmed, F. W., Hashim, S. M. A., & Waheed, N. (2024) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2024.361 · Cited by 11
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
Wang, J., Lin, C., Cai, X., Wang, Y., Wei, T., Wang, Y., Tie, C., Yang, Y., Lv, F., Yang, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16552 · Cited by 7
de Lucas, M. D. G., Caballero, I., Fernández‐García, J. C., Domínguez-Rodríguez, M., Moreno-Moreno, P., Jiménez-Millán, A., Botana-López, M. A., Avilés, B., Merino-Torres, J. F., Soto, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240279 · Cited by 10
Bachmakova, M., Buyukbabani, M. B., Dranseika, V., Brown, R. C. H., Devolder, K., Ryan, N., Savulescu, J., Everett, J. A. C., Hannikainen, I. R., & Earp, B. D. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118657 · Cited by 10
Amamoo, J. J., Doshi, R., Noone, J., Xie, L. Y., Gamble, C. L., Guevarra, M., Divino, V. M., Chen, J., & King, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01721-y · Cited by 4
Frazer, M., Swift, C., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., Noone, J. M., & Gamble, C. L. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01341-y · Cited by 4
Rudofsky, G., Menzen, M., Potier, L., Catarig, A.-M., Clark, A., Priyadarshini, P., & Abreu, C. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03000-x · Cited by 3
Self-citationBuse, J. B., Christensen, H. N., Harty, B. J., Cziraky, M. J., Willey, V. J., & Skibsted, S. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005161 · Cited by 6
Pereira, A. W. M., Pereira, J. A., & Ferreira, S. (2024) · Research Society and Development · doi:10.33448/rsd-v13i7.46426 · Cited by 2
Milenković, T., Mitreva, B. C., Mishevska, S. J., Bitoska-Mileva, I., & Ahmeti, I. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111018 · Cited by 3
Buenaventura, D. C., Ramos, A. F. G., Valencia, C. M. B., Aguilar-Londoño, C., Coronel-Restrepo, N., Monsalve, C., Cuesta, D., & Rincón, A. R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1372992 · Cited by 2
Wang, S., Hu, P., Shen, Z., & Chen, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01848-6 · Cited by 1
“…insulin use at base-line and who continued semaglutide treat-ment for 6 months ( n = 1686; mean [SD] baseline daily dose 50.49 units [28.05]) and 12 months ( n = 484; mean [SD] baseline daily [26.23]), the mean daily insulin dose was significantly reduced at month 6 and 12 versus baseline (Fig.”
InfluentialSerpa-Díaz, D., Llanos-Florez, C. A., Uribe, R. A. S., Molina, D. I., Giraldo, G. C., Urina‐Triana, M., Suarez-Rodriguez, A. F., & Alzate-Vinasco, M. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01586-7 · Cited by 2
“This has been reported in other real‑world studies [13] and may be related to the differences in real‑life scenarios with those of the clinical trials, like lower adherence [25] and a more diverse population.”
Swift, C., Frazer, M., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., & Noone, J. M. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.12.014 · Cited by 2
Boregowda, K., & Bain, S. C. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.443
Sümbül, H. E., Işık, B., Mustan, A. G., Alişan, İ., Erhan, Ç., Koca, F. I., Uçar, A., Erdevir, M., Avcı, B. Ş., Sumbul, M. S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114105
“Previous real-world studies have reported the beneficial effects of semaglutide treat-ment on HbA1c levels, body weight, dyslipidemia, and reductions in insulin dose and https://doi.org/10.3390/jcm15114105 injection frequency among patients with T2DM [12–23].”
InfluentialReal World Evidences and Identifying the Gaps and Future Prospects with Incretin Therapy in India
Khare, J., Ghosh, M. A., Kaduskar, A., Babu, V., Mohan, B. J., AHMED, D. R., Poul, S., Singh, M. M., Gupta, R., Singh, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_26
Dizdarević-Bostandžić, A., Hadzigrahic, E., & Nišić, A. (2026) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2026-001616
Wang, M., Li, M., Yang, S., Zhang, H., & Liu, P. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/3238847
Wang, S., DONG, B., & Shen, Z. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01915-y
Metadata
- Authors
- Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S.
- Affiliations
- Gemeinschaftskrankenhaus Bonn, Innere Medizin – Diabetologie und Endokrinologie, Bonn, Germany
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (Germany) (DE)
- MVZ im Altstadt-Carree Fulda GmbH, Fulda, Germany
- Cardio-metabolic Institute, Villingen, Germany
- Corresponding author
- Menzen, Markus
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2023-01-04
- Volume
- 131
- Issue
- 04
- Pages
- 205-215
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- PMC
- PMC10101737
- OpenAlex
- W4313490144
- Semantic Scholar
- a5be5ce62a72676bc1dfbea2df0e1f0192b58ca8
- Cited by
- 29
- References
- 28
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 7
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk (NA)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, glycemic control, weight loss, patient-reported outcomes, hypoglycemia, adverse events, real-world effectiveness, GLP-1 receptor agonists, clinical practice
- MeSH terms
- Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.